Gene Editing for Neurological Disorders: A Synthesis and Proposed Neuroethical Stewardship Model

Gene editing technologies, particularly CRISPR-Cas9 and its variants, offer transformative therapeutic potential for neurological disorders including Alzheimer's, Parkinson's, Huntington's, ALS, and epileptic syndromes. This paper synthesizes current preclinical and early clinical research on gene editing applications in the central nervous system, examines conflicting findings across key disease models, and analyzes delivery challenges posed by the blood-brain barrier. Drawing on literature from Nature Medicine, Nature Neuroscience, Nature Biotechnology, Cell, and Nature Communications, the paper proposes an original Neuroethical Stewardship Model — a four-part framework prioritizing somatic-centered interventions, adaptive regulation, public engagement, and risk-benefit triangulation. The model argues that responsible translation of gene editing into neurology requires ongoing ethical oversight commensurate with the pace of scientific advancement.